Search results
Results from the WOW.Com Content Network
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
Withdrawn due to risk of intussusception. [47] Rimonabant (Acomplia) 2008 Worldwide Risk of severe depression and suicide. [14] Rofecoxib 2004 Worldwide Withdrawn by Merck & Co. Risk of myocardial infarction and stroke. [2] Rosiglitazone (Avandia) 2010 Europe Risk of heart attacks and death. This drug continues to be available in the US ...
However, the court denied the motion to dismiss on the grounds, because the complaint sufficiently alleged that Pfizer had worked in concert with the Nigeria government, thereby Pfizer acted as a "de facto state actor". [citation needed] Next, Pfizer sought dismissal on grounds of forum non conveniens [citation needed]. Despite the plaintiff's ...
(Reuters) -A federal judge on Monday dismissed a lawsuit by a major pharmaceutical industry trade association challenging a new program that allows Medicare to negotiate prices with drug companies ...
Nov. 13—A Westmoreland County judge on Monday dismissed criminal charges against a Southwest Greensburg woman who prosecutors said was responsible for the fatal overdose of her live-in boyfriend ...
The following is a list of the 21 largest civil settlements, reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2017, ordered by the size of the total civil settlement. Some of these matters also resolved criminal fines and penalties, listed in parentheses, but these amounts are not considered when ...
"The judge today ruled to dismiss this case just as the DOJ - which launched three separate probes - and the Manhattan district attorney did previously," a Cuomo rep said.
Faster drug approval times and other PDUFA-related changes have led to pharmaceutical companies targeting more drugs for first launch in the United States thus increasing patient access to new medicines. Faster drug review from 1990 to 2001 were found to increase the probability of a drug being launched first in the United States by 14%.